WAT

Waters is a high-quality analytical instruments franchise (LC/LC‑MS, separations, software and services) with an entrenched installed base that drives recurring revenue and switching costs, especially in regulated pharma QC. A major 2026 development is the completed combination with BD’s Biosciences & Diagnostic Solutions businesses (closed February 9, 2026), which meaningfully expands Waters’ addressable market into high‑volume diagnostics and broadens its consumables/service mix. The opportunity is durable, but integration execution and keeping innovation velocity high alongside a much larger organization will be key.

Standalone Waters exited 2025 with sales of $3.165B (+7% reported) and non‑GAAP EPS of $13.13 (GAAP EPS $10.76). Profitability is strong on a trailing basis (operating margin ~28.1%, net margin ~20.3%, ROE ~29.3%), and TTM net income is about $643M on $3.17B revenue; leverage is set to rise given deal financing, though liquidity/cash coverage details are limited here. Valuation looks full for a cyclical-capex name at ~26–28x trailing P/E, with the market now underwriting synergy delivery and faster growth.

Over the next 12 months, the thesis hinges on whether management hits early BD integration milestones while protecting core LC‑MS momentum and service attachment. Catalysts include synergy realization and evidence the combined diagnostics portfolio can sustain mid‑single‑digit+ organic growth; key risks are integration disruptions, higher interest expense/deleveraging pace, and any slowdown in pharma instrument demand. 2026 guidance is ambitious: total revenue $6.405–$6.455B and non‑GAAP EPS $14.30–$14.50.

Recommendation: HOLD. The combined company has improved growth and recurring-revenue potential, but the post-deal complexity and a still-demanding earnings multiple limit near-term upside unless integration execution is clearly ahead of plan.